Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 24Unknown 5Terminated 5Recruiting 3Active not recruiting 3Withdrawn 2Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Pancreatic Neoplasms 4Breast Neoplasms 3Sarcoma 2Neoplasms 2Glioblastoma 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Brain Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Localized Resectable Adult Primary Liver Cancer 1Jaundice 1Esophageal Neoplasms 1Duodenal Neoplasms 1Colonic Neoplasms 1Clinical Stage I Gastric Cancer AJCC v8 1Childhood Brain Neoplasm 1Carcinoma, Hepatocellular 1Bites and Stings 1Biliary Tract Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Temozolomide 9Magnetic Resonance Spectroscopy 9Bevacizumab 8Radiotherapy 4Radiation 4Lomustine 3Carmustine 3pembrolizumab 2dexamethasone acetate 2atezolizumab 2TIC10 compound 2Surgical Procedures, Operative 2Sunitinib 2Standard of Care 2Specimen Handling 2Sorafenib 2Radiosurgery 2Irinotecan 2Dexamethasone 2Carboplatin 2Calcium Dobesilate 2Axitinib 2Aminolevulinic Acid 2vocimagene amiretrorepvec 1tandutinib 1poly ICLC 1pazopanib 1niraparib 1keyhole-limpet hemocyanin 1gallium Ga 68 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Glioblastoma × Surgical Procedures, Operative × Clear all
NCT06328036 2024-12-30

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
CNS

Glioblastoma

NCT03480867 2019-08-14

PARADIGMA

McGill University Health Centre/Research Institute of the McGill University Health Centre

Phase 1 Withdrawn
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡